Crestline Management’s Foamix Pharmaceuticals Ltd. Ordinary Shares FOMX Stock Holding History

Crestline Management’s Portfolio FOMX Stock Details FOMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-217,670	Closed	-$1.09M	–	270
2018 Q2	$1.09M	Hold	217,670	–	–	0.11%	189
2018 Q1	$1.12M	Buy	217,670 +44,169	+25%	+$266K	0.14%	136
2017 Q4	$1.04M	Hold	173,501	–	–	0.11%	107
2017 Q3	$963K	Sell	173,501 -3,987	-2%	-$20.6K	0.13%	100
2017 Q2	$824K	Buy	177,488 +75,788	+75%	+$338K	0.11%	94
2017 Q1	$819K	Buy	+101,700	New	+$979K	0.15%	65

Other funds holding FOMX

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

DCM

DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return

Crestline Management's FOMX Position: Q3 2018 in Review

Crestline Management sold out of Foamix Pharmaceuticals Ltd. Ordinary Shares (FOMX) in Q3 2018, closing a stake of 217,670 shares — an estimated $1.09M sold.

Crestline Management first reported a position in FOMX in Q1 2017 and held it in 6 quarters. The position peaked at $1.12M in Q1 2018. 75 funds tracked by Wall St. Rank hold FOMX as of Q3 2018.

Crestline Management reported no remaining Foamix Pharmaceuticals Ltd. Ordinary Shares position as of Q3 2018 after selling out during the quarter.
Crestline Management sold 217,670 Foamix Pharmaceuticals Ltd. Ordinary Shares shares in Q3 2018, an estimated $1.09M.
Crestline Management first reported a position in Foamix Pharmaceuticals Ltd. Ordinary Shares in Q1 2017 and held it in 6 quarters.
Crestline Management's Foamix Pharmaceuticals Ltd. Ordinary Shares position peaked at $1.12M in Q1 2018.
75 funds tracked by Wall St. Rank held Foamix Pharmaceuticals Ltd. Ordinary Shares as of Q3 2018.

Based on Crestline Management's 13F filing for Q3 2018, filed 14 Nov 2018.